Atorvastatin calcium: SPECIAL PATIENT POPULATIONS Women(2)
Eleven per cent of the patient population studied in the clinical trials with atorvastatin were elderly patients (70 years of age or older) . Subset analysis of pooled data from the clinical trials showed that the effectiveness of atorvastatin was similar in elderly and younger patients. In both patient groups there is a consistent dose-dependent reduction in LDL-C level across the recommended dose range for atorvas-tatin (Table 6). Results from the clinical trials described above also demonstrate consistency between elderly and younger patients in modifications of other lipoprotein fractions (total cholesterol, triglycerides, VLDL-C, apo B, HDL-C, etc).
TABLE 6 Efficacy of low density lipoprotein cholesterol lowering in elderly and young patients: Subset analysis from pooled studies (mild to moderate hypercholesterolemia)
|Atorvastatin dose||Age <70 years (n=1803)||Age >70 years (n=221)|
Based on data from reference 70
Patients with type II diabetes mellitus and hyperlipidemia
Patients with type II buy diabetes drugs mellitus frequently have combined (mixed) dyslipidemia ; this adds to the overall cardiovascular disease risk in these patients. In a pilot, open-label study in patients with type II diabetes, atorvastatin 10 mg/day administered for four weeks reduced LDL-C levels by 39% compared with a 30% reduction observed with simvastatin 10 mg/day . Neither agent adversely affected glycemic control. In another six-month, double-blind, randomized, comparative study in patients with type II diabetes and dyslipidemia, treatment with atorvastatin 10 or 20 mg/ day resulted in more favourable changes in lipoprotein levels than did simvastatin treatment (10 or 20 mg/day) . Although the changes in LDL-C and HDL-C levels were comparable, atorvastatin was significantly more effective in reducing levels of total cholesterol, apo B, triglycerides and VLDL triglycerides. The study also allowed for a dose titration if patients did not reach their LDL-C target goal with the initial 10 mg/day dose. At the end of the six-month study period, a higher proportion of patients in the simvastatin group required titration to a higher dose (20 mg/day) than in the atorvastatin treatment group. Forty-six per cent of ator-vastatin-treated patients achieved their LDL-C target level compared with 26% of patients treated with simvastatin.